SWC
CRSP icon

Spectrum Wealth Counsel’s CRISPR Therapeutics CRSP Stock Holding History

Spectrum Wealth Counsel’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$137 Hold
4
– – ﹤0.01% 365
2024
Q4 		$158 Hold
4
– – ﹤0.01% 359
2024
Q3 		$188 Hold
4
– – ﹤0.01% 380
2024
Q2 		$217 Hold
4
– – ﹤0.01% 371
2024
Q1 		$273 Sell
4
-400
-99% -$28.6K ﹤0.01% 366
2023
Q4 		$25.3K Buy
+404
New +$22.3K ﹤0.01% 220

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Spectrum Wealth Counsel's CRSP Position: Q1 2025 in Review

Spectrum Wealth Counsel held its CRISPR Therapeutics (CRSP) position steady in Q1 2025 at 4 shares worth $137. The position accounts for ﹤0.01% of the portfolio, ranked #365.

Spectrum Wealth Counsel first reported a position in CRSP in Q4 2023 and has held it in 6 quarters since. The position peaked at $25.3K in Q4 2023. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Spectrum Wealth Counsel held 4 shares of CRISPR Therapeutics worth $137 as of Q1 2025.
  • Spectrum Wealth Counsel left its CRISPR Therapeutics share count unchanged in Q1 2025.
  • CRISPR Therapeutics made up ﹤0.01% of Spectrum Wealth Counsel's portfolio in Q1 2025, its #365 holding.
  • Spectrum Wealth Counsel first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • Spectrum Wealth Counsel's CRISPR Therapeutics position peaked at $25.3K in Q4 2023.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Spectrum Wealth Counsel's 13F filing for Q1 2025, filed 7 May 2025.